's Bulletin Board Post New Topic  
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
»'s Bulletin Board » Stock Picks Only » PARS

 - UBBFriend: Email this page to someone!    
Author Topic: PARS

Member Rated:
Icon 1 posted      Profile for keithsan         Edit/Delete Post 
This one isn't quite 5$, just shy. I never visit this board on allstocks but I feel this is an excellent stock. Check it out yourselves. I bought a while back and now I'm sitting on free shares. Its a med stock with a few drugs undergoing FDA testing and one is on stage 3. It's a steady climber with no FDA approvals yet.! Almost hit 5.00 2 days ago and then retraced.

I didn't see it listed here and currently I am only involved in smaller pennys. I thought someone else may be interested.

Trend Spotter (TM) Buy

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Hold
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Hold

Short Term Indicators Average: 60% - Buy
20-Day Average Volume - 953970

Medium Term Indicators
40 Day Commodity Channel Index Hold
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 75% - Buy
50-Day Average Volume - 1085874

Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy

Long Term Indicators Average: 100% - Buy
100-Day Average Volume - 1769998

Overall Average: 80% - Buy

Price Support Pivot Point Resistance

4.50 4.09 4.52 4.95

Today's Opinion:
80% Buy

Yesterday's Opinion:
96% Buy

Last Week's Opinion:
56% Buy

Last Month's Opinion:
88% Buy

Posts: 9110 | From: boston, ma | Registered: Jan 2004  |  IP: Logged | Report this post to a Moderator

Member Rated:
Icon 1 posted      Profile for keithsan         Edit/Delete Post 
Up .50 this am in pre-market trading!

Pharmos Completes Enrollment of Brain Injury Patients in Phase III Study of Dexanabinol
Monday March 15, 4:02 pm ET
Study Results Expected Around Yearend

ISELIN, N.J., March 15 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS - News) announced today that it has completed patient enrollment in its pivotal Phase III study of dexanabinol for the treatment of severe traumatic brain injury (TBI). The planned recruitment of 860 patients was completed with enrollment of a patient at the University of Virginia neurosurgery unit. A total of 86 trauma centers throughout the U.S., Europe, Israel and Australia participated in the study. The Company expects to unblind the study data and announce initial results near the end of this year.

"Our efforts are now centered on collecting all the relevant data as required by the trial protocol," said Gad Riesenfeld, Ph.D., President and COO.

"I am very satisfied with the quality of the study," said Andrew I.R. Maas, M.D., Director of Neurosurgical Intensive Care, Erasmus University Medical Center, Rotterdam, the Netherlands, Chairman of the European Brain Injury Consortium, and the head of the dexanabinol trial Steering Committee. "We believe that taken together, the study design as reflected in the clinical protocol, the statistical plan, and the dedicated work of the study investigators and the steering committee, are providing the best opportunity for the Company to demonstrate the neuroprotective activity of dexanabinol in TBI patients."

The purpose of the double-blinded, placebo controlled study is to evaluate the efficacy and safety of dexanabinol as a neuroprotectant agent in severe TBI patients. Enrolled patients were given a single dose of 150mg dexanabinol or (placebo) vehicle within six hours after injury and received the standard care normally provided to TBI patients in intensive care units. The primary endpoint for the study will be patient outcome as measured on the Glasgow Outcome Scale - Extended (GOSE) six months after injury.

Pharmos discovers, develops, and commercializes novel therapeutics to treat a range of indications, in particular neurological and inflammation- based disorders. The Company's first neuroprotective product is dexanabinol, a tricyclic dextrocannabinoid, currently undergoing clinical testing as a treatment for TBI and as a preventive agent against post-surgical cognitive impairment. Other dextrocannabinoid compounds and CB2 receptor agonist compounds from Pharmos' proprietary synthetic cannabinoid library are being studied in pre-clinical programs targeting a variety of other disorders.

Statements made in this press release related to the business outlook and future financial performance of the Company, to the prospective market penetration of its drug products, to the development and commercialization of the Company's pipeline products and to the Company's expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties which may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.

Source: Pharmos Corporation

Email this story - Set a News Alert

Posts: 9110 | From: boston, ma | Registered: Jan 2004  |  IP: Logged | Report this post to a Moderator

Member Rated:
Icon 1 posted      Profile for keithsan         Edit/Delete Post 
Some grant money here.

Posts: 9110 | From: boston, ma | Registered: Jan 2004  |  IP: Logged | Report this post to a Moderator

Member Rated:
Icon 1 posted      Profile for keithsan         Edit/Delete Post 
.M. Dutton & Associates Announces Investment Opinion: Pharmos Speculative Buy Rating Maintained In Update Coverage By Dutton & Associates
Wednesday April 14, 9:01 am ET

EL DORADO HILLS, Calif.--(BUSINESS WIRE)--April 14, 2004--JM Dutton & Associates updates coverage of Pharmos Corporation (Nasdaq:PARS - News) maintaining a Speculative Buy rating and a $4.50 price target. The 7-page report by JM Dutton senior analyst Sherry Grisewood, CFA is available at as well as from First Call, Bloomberg, Zacks, Reuters, and other leading financial portals.
The clinical program for Pharmos' lead compound, dexanabinol, is progressing on schedule. Patient enrollment for the Company's Phase III traumatic brain injury (TBI) trial was completed in March 2004. The six-month follow-up period ends in late summer/early fall, thus we expect significant Company activity in upcoming months. Management has maintained a high level of vigilance over the dexanabinol trials, and we remain confident of the drug's successful completion of the regulatory process. Dexanabinol would then become the first, and only, approved treatment for TBI, thus potentially opening a $1 billion market. The Company's Phase II trial has reached two-thirds of its patient enrollment objective and will produce data during the second half of this year. A further catalyst for increased investor interest in the upcoming months is the pending approval of the Company's ophthalmic treatment to be marketed by partner Bausch & Lomb.

Posts: 9110 | From: boston, ma | Registered: Jan 2004  |  IP: Logged | Report this post to a Moderator

Post New Topic   Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:

Contact Us | Message Board Home

© 1997 - 2019 All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2